Cortexolone 17α-propionate (clascoterone) is a novel androgen antagonist that is currently being analyzed in a large phase 2 clinical trial for the topical treatment of androgenetic alopecia (AGA). While the pathogenesis of AGA is still debated, the consensus is that AGA is an androgen-dependent hair disorder with strong genetic links, and that the testosterone metabolite, dihydrotestosterone (DHT), plays a causal role in its development. DHT binds to the androgen receptor (AR) in scalp dermal papilla cells (DPC) to induce AR-mediated transcription of genes that contribute to AGA in genetically predisposed individuals. Several studies have established that clascoterone is a potent antiandrogen that is well tolerated and has selective topical activity. The study described herein elucidates a potential mechanism of clascoterone in AGA. Clascoterone was found to inhibit AR-regulated transcription in a reporter cell line with similar efficacy to the 5α-reductase inhibitor, finasteride. More importantly, when compared with another direct AR antagonist, enzalutamide, clascoterone was significantly better at inhibiting IL-6 synthesis from DHT-stimulated primary cultures of human scalp DPC. Therefore, clascoterone may be an excellent candidate to be the first topical antiandrogen for treating AGA. J Drugs Dermatol. 2019;18(2):197-201.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Innovations in Acne.
Dermatol Clin
January 2025
Department of Dermatology, Brigham and Women's Hospital, 41 Avenue Louis Pasteur, 317A, Boston, MA 02115, USA. Electronic address:
Although many treatments are available for acne, these can be limited by lack of effectiveness, patient tolerance and adherence, and accessibility. This review provides a comprehensive summary of the latest developments in acne management, exploring a range of topical, systemic, and procedural treatments. The mechanisms of action, pivotal trial data, and potential role in clinical practice are reviewed for emerging therapies such as 1726 nm laser, sarecycline, clascoterone, trifarotene, minocycline foam, and fixed-dose combination topicals.
View Article and Find Full Text PDFEvaluation of in vitro Skin Permeation of Clascoterone From Clascoterone Topical Cream, 1% (w/w).
AAPS PharmSciTech
August 2024
Office of Pharmaceutical Quality Research, CDER, U.S. FDA, 10903 New Hampshire Avenue, WO64-Rm1032, Silver Spring, MD, 20993, USA.
Article Synopsis
- Winlevi (clascoterone) topical cream was FDA-approved for treating acne in patients aged 12 and older, but clascoterone's instability complicates its study in vitro.
- The study aimed to create an in vitro skin permeation test (IVPT) to accurately measure clascoterone levels while reducing hydrolyzation to cortexolone.
- Two IVPT methods were compared, revealing that flow-through cells significantly reduced degradation of clascoterone, highlighting the necessity of optimizing testing methods during product development.
Plasma 21-deoxycortisone: a sensitive additive tool in 21-hydroxylase deficiency in newborns.
Eur J Endocrinol
August 2024
Département de Métabolomique Clinique, Hôpital Saint Antoine, AP-HP.Sorbonne Université, 27 Rue Chaligny, 75012 Paris, France.
Objective, Design, And Methods: Although 17-hydroxyprogesterone (17OHP) has historically been the steroid assayed in the diagnosis of congenital adrenal 21-hydroxylase deficiency (CAH-21D), its C11-hydroxylated metabolite, 21-deoxycortisol (21DF), which is strictly of adrenal origin, is assayed in parallel in this pathology. This steroid (21DF) is oxidized by 11beta-hydroxysteroid dehydrogenase type 2 into 21-deoxycortisone (21DE). In the context of CAH-21D confirmation testing, confounding factors (such as intensive care unit admission, stress, prematurity, early sampling, and variations of sex development) can interfere with the interpretation of the gold-standard biomarkers (17OHP and 21DF).
View Article and Find Full Text PDFAdult Female Acne: Managing the Hormones.
Skin Therapy Lett
July 2024
Division of Dermatology, University of Ottawa, Ottawa, ON, Canada.
Acne is a common inflammatory condition of the skin worldwide. The skin is an endocrine organ and hormones are a key pathogenic factor in all types of acne with a particularly important role in adult female acne pathogenesis and management. In females, we have the unique opportunity to manipulate hormones systemically to successfully manage acne and, more recently with the approval of clascoterone 1% cream, we can target the hormones topically in both genders.
View Article and Find Full Text PDFThe gut microbial composition in polycystic ovary syndrome with hyperandrogenemia and its association with steroid hormones.
Front Cell Dev Biol
May 2024
Department of Research and Education, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University, Shanghai, China.
Polycystic ovary syndrome (PCOS) is characterized by excess androgens, ovulatory dysfunction, and polycystic ovaries. The mechanisms underlying ovulatory and metabolic disorders in PCOS remain elusive, hampering therapeutic development. Enhanced metabolic health correlates with increased microbiota gene content and microbial diversity.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!